Curtis Triplitt
Overview
Explore the profile of Curtis Triplitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baskoy G, Peterson R, Kempenich J, Triplitt C, Brown M, Clarke G, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39689013
Context: Increased mesenteric visceral fat is associated with the metabolic syndrome, insulin resistance, and type 2 diabetes. Methods: Using Targeted Cell Separation and Extraction Technology (TC-SET), we examined the effect...
2.
Cersosimo E, YueJuan Q, Baskoy G, Chavez A, Barkhordarian M, Hansis-Diarte A, et al.
Diabetes Obes Metab
. 2024 Nov;
27(2):944-952.
PMID: 39604709
Aims: To investigate the effect of sodium-glucose co-transporter 2 inhibitor [SGLT-2i] therapy on renal haemodynamics in T2D patients with glomerular hyperfiltration. Materials And Methods: Sixty T2D patients with elevated [HYPER]...
3.
Solis-Herrera C, Qin Y, Honka H, Cersosimo E, Triplitt C, Neppala S, et al.
Diabetes
. 2024 Oct;
74(1):43-52.
PMID: 39446133
Article Highlights:
4.
Goldman J, Triplitt C, Isaacs D
Ann Pharmacother
. 2024 Oct;
:10600280241287790.
PMID: 39425483
Objective: To evaluate the efficacy, safety, and clinical implications of insulin icodec, a novel once-weekly basal insulin for the treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D),...
5.
Merovci A, Finley B, Hansis-Diarte A, Neppala S, Abdul-Ghani M, Cersosimo E, et al.
BMJ Open Diabetes Res Care
. 2024 Oct;
12(5).
PMID: 39424350
Introduction: Low carbohydrate ketogenic diets have received renewed interest for the treatment of obesity and type 2 diabetes. These diets promote weight loss, improve glycemic control, and reduce insulin resistance....
6.
Solis-Herrera C, Kane M, Triplitt C
Clin Diabetes
. 2024 Jan;
42(1):74-86.
PMID: 38230324
Oral administration of peptide therapeutics faces challenges because of the distinct environment of the gastrointestinal tract. An oral formulation of semaglutide, a glucagon-like peptide 1 receptor agonist, was approved by...
7.
Abdelgani S, Khattab A, Adams J, Baskoy G, Triplitt C, DeFronzo R, et al.
Diabetes Obes Metab
. 2023 Dec;
26(3):1033-1039.
PMID: 38131252
Aim: To examine the impact of increased hepatic glucose production (HGP) on the decrease in plasma glucose concentration caused by empagliflozin in individuals living with diabetes and in nondiabetic individuals....
8.
Solis-Herrera C, Triplitt C
Diabetes Obes Metab
. 2023 Oct;
26(2):417-430.
PMID: 37885354
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is a major health challenge associated with a disproportionately high burden of end-stage renal disease, cardiovascular disease and death....
9.
Cersosimo E, Alatrach M, Solis-Herrera C, Baskoy G, Adams J, Hansis-Diarte A, et al.
J Clin Endocrinol Metab
. 2023 Jul;
109(1):161-170.
PMID: 37481263
Context: This study addresses the development of a new glucoregulatory mechanism in type 2 diabetes (T2D) patients treated with SGLT-2 inhibitors, which is independent of glucose, insulin and glucagon. The...
10.
Cincotta A, Cersosimo E, Alatrach M, Ezrokhi M, Agyin C, Adams J, et al.
Int J Mol Sci
. 2022 Aug;
23(16).
PMID: 36012132
Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population...